Mochi Health Treatments Weight loss GLP-1/GIP injectables (tirzepatide: Zepbound/Mounjaro), GLP-1 injectables (semaglutide: Wegovy/Ozempic
Despite the availability of six FDA-approved anti-obesity medications (AOMs) for chronic weight management, current guidelines recommend waiting six months after behavioral therapy begins before adding pharmacological support
This dual action of eating less and burning more simultaneously is what produces results that exceed the purely restriction-based mechanism of older GLP-1 compounds
For a comprehensive overview, see: Reta Peptide: Structure, Classification & Research Overview
However, as it is not yet approved, there are no official prescribing guidelines or standard dosing recommendations for public use
Some add coaching layers that either genuinely help or just inflate the monthly cost